Deadline on September 7, 2021, in Lawsuit for Investors in shares of Orphazyme A/S (NASDAQ: ORPH) – Press Release


A Deadline is coming up on September 7, 2021 in the lawsuit for certain investors in Orphazyme A/S (NASDAQ: ORPH).

A Deadline is coming up on September 7, 2021 in the lawsuit for certain investors in Orphazyme A/S (NASDAQ: ORPH).

A deadline is coming up on September 7, 2021 in the lawsuit filed for certain investors of Orphazyme A/S (NASDAQ: ORPH) over alleged securities laws violations by Orphazyme A/S.

Investors who purchased shares of Orphazyme A/S (NASDAQ: ORPH) have certain options and there are strict and short deadlines running. Deadline: September 7, 2021. NASDAQ: ORPH stockholders should contact the Shareholders Foundation at [email protected] or call +1(858) 779 – 1554.

The plaintiff alleges on behalf of purchasers of Orphazyme A/S (NASDAQ: ORPH) common shares, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that the Offering Documents were negligently prepared and, as a result, contained untrue statements of material fact or omitted to state other facts necessary to make the statements made not misleading and were not prepared in accordance with the rules and regulations governing their preparation.

Additionally, the complaint alleges that, the Offering Documents and Defendants made false and/or misleading statements and/or failed to disclose that arimoclomol was not as effective in treating IBM as Defendants had represented, that arimoclomol was not as effective in treating ALS as Defendants had represented, that the arimoclomol NDA for NPC was incomplete and/or required additional evidence and data to support the benefit-risk assessment of that NDA, that as a result of , that the FDA was unlikely to approve the arimoclomol NDA for NPC in its present form, that the Company’s overall business prospects, as well as arimoclomol’s commercial prospects, were significantly overstated, and that as a result, the Offering Documents and Defendants’ public statements between September 29, 2020 and June 18, 2021 were materially false and/or misleading and failed to state information required to be stated therein.

Those who purchased shares of Orphazyme A/S (NASDAQ: ORPH) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: [email protected]

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.